CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 和新型免疫治疗时代复发/难治性弥漫大 B 细胞淋巴瘤患者的姑息治疗和临终关怀利用情况
英文原题：Palliative care and hospice utilization in patients with relapsed or refractory diffuse large B-cell lymphoma in the era of CART and novel immunotherapies.
查看英文原题
Palliative care and hospice utilization in patients with relapsed or refractory diffuse large B-cell lymphoma in the era of CART and novel immunotherapies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞疗法（CAR-T）已改变了复发/难治性弥漫大B细胞淋巴瘤（r/r DLBCL）的治疗，但大多数患者仍死于该病，可能受益于姑息治疗（PC）或临终关怀服务。CAR-T 的可及性是否影响了PC或临终关怀转诊模式及临终结局仍不清楚。
我们开展了一项单中心回顾性研究，针对r/r DLBCL已故患者，评估CAR-T 引入前后的PC和临终关怀使用情况（CAR-T 前87例，CAR-T 后95例）。两个时期的PC转诊率相似（57.5% vs 70.5%，p = 0.39），临终关怀转诊率也相似（79.3% vs 83.2%，p = 0.78）。
然而，CAR-T 后时期的患者从末次治疗到死亡的时间更短（95 vs 51天，p = 0.001），生命最后30天的住院率更高（57.5% vs 72.6%，p = 0.03），院内死亡更多（19.5% vs 33.7%，p = 0.045）。总体而言，20-30%的患者从未被转诊至PC或临终关怀。
展开英文摘要原文
Chimeric antigen receptor T-cell therapy (CART) has changed treatment for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL), but most patients still die of their disease and may benefit from palliative care (PC) or hospice services. Whether CART availability has affected PC or hospice referral patterns and end-of-life outcomes remains unclear.
We conducted a single-center retrospective study for deceased patients with r/r DLBCL to evaluate PC and hospice utilization before and after CART introduction (87 pre-CART, 95 post-CART). PC referral rates were similar between eras (57. 5% vs 70. 5%, p = 0. 39), as were hospice referrals (79. 3% vs 83. 2%, p = 0. 78).
However, patients in the post-CART era had shorter time from last treatment to death (95 vs 51 days, p = 0. 001), higher hospitalization rates in the last 30 days of life (57. 5% vs 72. 6%, p = 0. 03), and more in-hospital deaths (19. 5% vs 33. 7%, p = 0. 045).
Overall, 20-30% of patients were never referred to PC or hospice.
论文信息
- 作者
- Trotier D、Liu M、Augustine A、Vembu K、Trainor M、Pophali P
- 单位
- Department of Medicine, Division of Hematology, Medical Oncology and Palliative Care, University of Wisconsin, Madison, WI, USA.United States
- 期刊
- Leukemia & lymphoma2026 Aug 16
- 原文标识
- PubMed 42604568 · DOI 10.1080/10428194.2026.2715204